No Data
No Data
Strong Week for Aclaris Therapeutics (NASDAQ:ACRS) Shareholders Doesn't Alleviate Pain of Three-year Loss
Aclaris Therapeutics: FDA Clears IND Application For Phase 1A/1B Clinical Trial Of ATI-052, Bispecific Anti-TSLP/IL-4R Monoclonal Antibody; Co. Expects To Initiate Trial In Q2
Express News | Aclaris Therapeutics Secures U.S. Food and Drug Administration Ind Clearance for ATI-052, Enabling Advancement of Its Novel Bispecific Anti-Tslp/Il-4R Investigational Antibody
Aclaris Therapeutics Assumed With an Overweight at Cantor Fitzgerald
Cantor Fitzgerald Initiates Aclaris Therapeutics(ACRS.US) With Buy Rating
Cantor Fitzgerald Reiterates Overweight on Aclaris Therapeuticsto Overweight
Growth lover : time to buy